

# Charles V Pollack

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2976638/publications.pdf>

Version: 2024-02-01

96  
papers

6,740  
citations

185998

28  
h-index

60497

81  
g-index

96  
all docs

96  
docs citations

96  
times ranked

7233  
citing authors

#	ARTICLE	IF	CITATIONS
1	Idarucizumab for Dabigatran Reversal. <i>New England Journal of Medicine</i> , 2015, 373, 511-520.	13.9	1,419
2	Baseline Risk of Major Bleeding in Non-“ST-Segment” Elevation Myocardial Infarction. <i>Circulation</i> , 2009, 119, 1873-1882.	1.6	876
3	Idarucizumab for Dabigatran Reversal “ Full Cohort Analysis. <i>New England Journal of Medicine</i> , 2017, 377, 431-441.	13.9	858
4	Clinical Characteristics, Management, and Outcomes of Patients Diagnosed With Acute Pulmonary Embolism in the Emergency Department. <i>Journal of the American College of Cardiology</i> , 2011, 57, 700-706.	1.2	438
5	2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. <i>Journal of the American College of Cardiology</i> , 2017, 70, 3042-3067.	1.2	285
6	Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. <i>Lancet</i> , The, 2011, 378, 693-703.	6.3	264
7	The Association Between Emergency Department Crowding and Adverse Cardiovascular Outcomes in Patients with Chest Pain. <i>Academic Emergency Medicine</i> , 2009, 16, 617-625.	0.8	247
8	Application of the TIMI Risk Score for Unstable Angina and Non-ST Elevation Acute Coronary Syndrome to an Unselected Emergency Department Chest Pain Population. <i>Academic Emergency Medicine</i> , 2006, 13, 13-18.	0.8	218
9	Acute Clopidogrel Use and Outcomes in Patients With Non-“ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery. <i>Journal of the American College of Cardiology</i> , 2006, 48, 281-286.	1.2	179
10	Recent Trends in the Care of Patients With Non-“ST-Segment Elevation Acute Coronary Syndromes. <i>Archives of Internal Medicine</i> , 2006, 166, 2027.	4.3	153
11	Improving the Care of Patients with Non-ST-elevation Acute Coronary Syndromes in the Emergency Department: The CRUSADE Initiative. <i>Academic Emergency Medicine</i> , 2002, 9, 1146-1155.	0.8	137
12	Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. <i>Thrombosis and Haemostasis</i> , 2015, 114, 198-205.	1.8	132
13	Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers. <i>New England Journal of Medicine</i> , 2019, 380, 1825-1833.	13.9	96
14	Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Practice Guidelines for Management and Care Transitions in the Emergency Department and Hospital. <i>Journal of Emergency Medicine</i> , 2015, 48, 508-519.	0.3	88
15	Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non-“ST-segment elevation acute coronary syndrome. <i>American Heart Journal</i> , 2013, 165, 918-925.e2.	1.2	87
16	2007 Update to the ACC/AHA Guidelines for the Management of Patients With Unstable Angina and Non-“ST-Segment Elevation Myocardial Infarction: Implications for Emergency Department Practice. <i>Annals of Emergency Medicine</i> , 2008, 51, 591-606.	0.3	84
17	Clevidipine, an Intravenous Dihydropyridine Calcium Channel Blocker, Is Safe and Effective for the Treatment of Patients With Acute Severe Hypertension. <i>Annals of Emergency Medicine</i> , 2009, 53, 329-338.	0.3	84
18	A Prospective Multicenter Study of Patient Factors Associated With Hospital Admission From the Emergency Department Among Children With Acute Asthma. <i>JAMA Pediatrics</i> , 2002, 156, 934.	3.6	63

#	ARTICLE	IF	CITATIONS
19	Therapy and outcomes in massive pulmonary embolism from the Emergency Medicine Pulmonary Embolism in the Real World Registry. <i>American Journal of Emergency Medicine</i> , 2012, 30, 1774-1781.	0.7	60
20	2007 Focused Update to the ACC/AHA Guidelines for the Management of Patients With ST-Segment Elevation Myocardial Infarction: Implications for Emergency Department Practice. <i>Annals of Emergency Medicine</i> , 2008, 52, 344-355.e1.	0.3	48
21	Anticoagulant Reversal Strategies in the Emergency Department Setting: Recommendations of a Multidisciplinary Expert Panel. <i>Annals of Emergency Medicine</i> , 2020, 76, 470-485.	0.3	46
22	2002 update to the ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: Implications for emergency department practice. <i>Annals of Emergency Medicine</i> , 2003, 41, 355-369.	0.3	44
23	Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation. <i>Critical Care</i> , 2016, 20, 115.	2.5	40
24	Unfractionated heparin dosing and risk of major bleeding in non-ST-segment elevation acute coronary syndromes. <i>American Heart Journal</i> , 2008, 156, 209-215.	1.2	39
25	Early Glycoprotein IIb/IIIa Inhibitor Use for Non-ST-segment Elevation Acute Coronary Syndrome: Patient Selection and Associated Treatment Patterns. <i>Academic Emergency Medicine</i> , 2005, 12, 431-438.	0.8	37
26	Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding. <i>Circulation</i> , 2019, 139, 748-756.	1.6	36
27	Idarucizumab for dabigatran overdose. <i>Clinical Toxicology</i> , 2016, 54, 644-646.	0.8	30
28	Timing of Angiography and Outcomes in High-Risk Patients With Non-ST-Segment Elevation Myocardial Infarction Managed Invasively. <i>Circulation</i> , 2017, 136, 1895-1907.	1.6	29
29	Dabigatran Reversal With Idarucizumab in Patients Requiring Urgent Surgery. <i>Annals of Surgery</i> , 2021, 274, e204-e211.	2.1	27
30	EP-7041, a Factor XIa Inhibitor as a Potential Antithrombotic Strategy in Extracorporeal Membrane Oxygenation: A Brief Report. , 2020, 2, e0196.		27
31	A review of guidelines on anticoagulation reversal across different clinical scenarios – Is there a general consensus?. <i>American Journal of Emergency Medicine</i> , 2020, 38, 1890-1903.	0.7	26
32	Heliox for treatment of exacerbations of chronic obstructive pulmonary disease. <i>The Cochrane Library</i> , 2001, , CD003571.	1.5	24
33	Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1760-1768.	1.2	24
34	Timing of Glycoprotein IIb/IIIa Inhibitor Use and Outcomes Among Patients With Non-ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention (Results from) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 13		
35	Dabigatran Reversal with Idarucizumab. <i>New England Journal of Medicine</i> , 2017, 377, 1690-1692.	13.9	23
36	Creation and Implementation of an Outpatient Pathway for Atrial Fibrillation in the Emergency Department Setting: Results of an Expert Panel. <i>Academic Emergency Medicine</i> , 2018, 25, 1065-1075.	0.8	22

#	ARTICLE	IF	CITATIONS
37	Managing Bleeding in Anticoagulated Patients in the Emergency Care Setting. <i>Journal of Emergency Medicine</i> , 2013, 45, 467-477.	0.3	21
38	Priority Considerations for Medicinal Cannabis-Related Research. <i>Cannabis and Cannabinoid Research</i> , 2019, 4, 139-157.	1.5	21
39	Prognostic Value of Symptoms during a Normal or Nonspecific Electrocardiogram in Emergency Department Patients with Potential Acute Coronary Syndrome. <i>Academic Emergency Medicine</i> , 2006, 13, 1034-1039.	0.8	19
40	New oral anticoagulants in the ED setting: a review. <i>American Journal of Emergency Medicine</i> , 2012, 30, 2046-2054.	0.7	19
41	Prognostic Value of Troponins in Patients with Non-ST-segment Elevation Acute Coronary Syndromes and Chronic Kidney Disease. <i>Clinical Cardiology</i> , 2008, 31, 125-129.	0.7	18
42	Multicenter Trial of Rivaroxaban for Early Discharge of Pulmonary Embolism From the Emergency Department (MERCURY PE): Rationale and Design. <i>Academic Emergency Medicine</i> , 2016, 23, 1280-1286.	0.8	18
43	Non-ST-Elevation Myocardial Infarction Patients Who Present During Off Hours Have Higher Risk Profiles and are Treated Less Aggressively, but Their Outcomes are Not Worse. <i>Critical Pathways in Cardiology</i> , 2009, 8, 29-33.	0.2	17
44	Advanced Management of Acute Iliofemoral Deep Venous Thrombosis: Emergency Department and Beyond. <i>Annals of Emergency Medicine</i> , 2011, 57, 590-599.	0.3	17
45	The Usage Patterns of Cardiac Bedside Markers Employing Point-of-Care Testing for Troponin in Non-ST-segment Elevation Acute Coronary Syndrome: Results from CRUSADE. <i>Clinical Cardiology</i> , 2009, 32, 498-505.	0.7	16
46	Rates of hospitalization among patients with deep vein thrombosis before and after the introduction of rivaroxaban. <i>Hospital Practice (1995)</i> , 2015, 43, 85-93.	0.5	16
47	Relative efficacy and safety of ticagrelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial. <i>Clinical Cardiology</i> , 2017, 40, 390-398.	0.7	16
48	Patient-reported Outcomes from A National, Prospective, Observational Study of Emergency Department Acute Pain Management With an Intranasal Nonsteroidal Anti-inflammatory Drug, Opioids, or Both. <i>Academic Emergency Medicine</i> , 2016, 23, 331-341.	0.8	15
49	Interrater Reliability of Criteria Used in Assessing Blunt Head Injury Patients for Intracranial Injuries. <i>Academic Emergency Medicine</i> , 2003, 10, 830-835.	0.8	13
50	Evidence Supporting Idarucizumab for the Reversal of Dabigatran. <i>American Journal of Medicine</i> , 2016, 129, S73-S79.	0.6	12
51	Can Electrocardiographic Criteria Predict Adverse Cardiac Events and Positive Cardiac Markers?. <i>Academic Emergency Medicine</i> , 2003, 10, 205-210.	0.8	11
52	Antiplatelet Therapy in Acute Coronary Syndromes: The Emergency Physician's Perspective. <i>Journal of Emergency Medicine</i> , 2008, 35, 5-13.	0.3	11
53	Emergency Medicine and Hospital Medicine: A Call for Collaboration. <i>American Journal of Medicine</i> , 2012, 125, 826.e1-826.e6.	0.6	11
54	Improving acute pain management in emergency medicine. <i>Hospital Practice (1995)</i> , 2015, 43, 36-45.	0.5	11

#	ARTICLE	IF	CITATIONS
55	Evidence supporting idarucizumab for the reversal of dabigatran. <i>American Journal of Emergency Medicine</i> , 2016, 34, 33-38.	0.7	11
56	Emergency Medicine and Hospital Medicine: A Call for Collaboration. <i>Journal of Emergency Medicine</i> , 2012, 43, 328-334.	0.3	10
57	Intravenous Enoxaparin Versus Unfractionated Heparin in Elderly Patients Undergoing Primary Percutaneous Coronary Intervention. <i>Angiology</i> , 2017, 68, 29-39.	0.8	10
58	Incidence and consequence of major bleeding in primary percutaneous intervention for ST-elevation myocardial infarction in the era of radial access: an analysis of the international randomized Acute myocardial infarction Treated with primary angioplasty and intravenous enoxaparin Or unfractionated heparin to Lower ischemic and bleeding events at short- and Long-term follow-up trial. <i>American Heart Journal</i> , 2015, 170, 778-786.	1.2	9
59	The safety of oral anticoagulants registry (SOAR): A national, ED-based study of the evaluation and management of bleeding and bleeding concerns due to the use of oral anticoagulants. <i>American Journal of Emergency Medicine</i> , 2020, 38, 1163-1170.	0.7	9
60	Contemporary NSTEMI management: the role of the hospitalist. <i>Hospital Practice (1995)</i> , 2020, 48, 1-11.	0.5	9
61	Introduction to direct oral anticoagulants and rationale for specific reversal agents. <i>American Journal of Emergency Medicine</i> , 2016, 34, 1-2.	0.7	8
62	Identification of Patient Characteristics Influencing Setting of Care Decisions for Patients With Acute Bacterial Skin and Skin Structure Infections: Results of a Discrete Choice Experiment. <i>Clinical Therapeutics</i> , 2016, 38, 531-544.e9.	1.1	8
63	Wireless Cardiac Event Alert Monitoring is Feasible and Effective in the Emergency Department and Adjacent Waiting Areas. <i>Critical Pathways in Cardiology</i> , 2009, 8, 7-11.	0.2	7
64	Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD, a study. <i>Journal of Medical Economics</i> , 2017, 20, 435-442.	1.0	7
65	Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006084.	1.4	7
66	Sex Differences in Ischemic and Bleeding Outcomes in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e009759.	1.4	7
67	Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1319-1328.	1.9	5
68	Early Treatment for Non-ST-Segment Elevation Acute Coronary Syndrome Is Associated with Appropriate Discharge Care. <i>Clinical Cardiology</i> , 2009, 32, 519-525.	0.7	4
69	Acute Coronary Syndromes: From the Emergency Department to the Catheterization Laboratory-Integrating Evidence from Recent ACS/NSTEMI Trials into Clinical Practice: An Evidence-Based Review of Recent Clinical Trial Results and Report on a Roundtable Discu. <i>Journal of Interventional Cardiology</i> , 2011, 24, 119-136.	0.5	4
70	The use of oral anticoagulants for the treatment of venous thromboembolic events in an ED. <i>American Journal of Emergency Medicine</i> , 2014, 32, 1526-1533.	0.7	4
71	The Medical Management of Acute Coronary Syndromes and Potential Roles for New Antithrombotic Agents. <i>Journal of Emergency Medicine</i> , 2008, 34, 417-428.	0.3	3
72	Utility of platelet adp receptor antagonism in the emergency department: a review. <i>Journal of Emergency Medicine</i> , 2003, 24, 45-54.	0.3	2

#	ARTICLE	IF	CITATIONS
73	Emerging Oral Antiplatelet Therapies for Acute Coronary Syndromes. Hospital Practice (1995), 2010, 38, 29-37.	0.5	2
74	Atypical is becoming typical in ST-elevation myocardial infarction presentation, but delays persist for women. American Heart Journal, 2013, 166, 804-805.	1.2	2
75	Evidence for Basalâ€“Bolus Insulin Versus Slide Scale Insulin. Current Emergency and Hospital Medicine Reports, 2014, 2, 26-34.	0.6	2
76	Variation Between Physicians and Mid-level Providers in Opioid Treatment for Musculoskeletal Pain in the Emergency Department. Journal of Emergency Medicine, 2015, 49, 415-423.	0.3	2
77	Introduction to Direct Oral Anticoagulants and Rationale for Specific Reversal Agents. American Journal of Medicine, 2016, 129, S31-S32.	0.6	2
78	Pharmacological and mechanical revascularization strategies in STEMI: integration of the two approaches. Journal of Invasive Cardiology, 2008, 20, 231-8.	0.4	2
79	Influence of Clinical Trial Participation on Subsequent Antithrombin Use. Clinical Cardiology, 2010, 33, E49-55.	0.7	1
80	Long-term impact of routine versus invasive ACS management. Nature Reviews Cardiology, 2010, 7, 544-546.	6.1	1
81	Upstream antiactivation antiplatelet therapy: first, do no harm. Then consider doing some good. American Journal of Emergency Medicine, 2013, 31, 1408-1409.	0.7	1
82	Rationale for Upstream Dual Antiplatelet Therapy in Non-ST-Segment Elevation Myocardial Infarction. Current Emergency and Hospital Medicine Reports, 2014, 2, 76-89.	0.6	1
83	Dabigatran-related coagulopathy: when can we assume the effect has â€œworn offâ€?. American Journal of Emergency Medicine, 2014, 32, 1433-1434.	0.7	1
84	Balancing Anti-thrombotic Efficacy and Bleeding Risk in the Contemporary Management of Venous Thromboembolism. Current Emergency and Hospital Medicine Reports, 2015, 3, 89-99.	0.6	1
85	The Future of Aspirin Therapy in Cardiovascular Disease. American Journal of Cardiology, 2021, 144, S40-S47.	0.7	1
86	Evolution of Clinical Thinking and Practice Regarding Aspirin: What Has Changed and Why?. American Journal of Cardiology, 2021, 144, S10-S14.	0.7	1
87	Oral Antiplatelet Therapy Administered Upstream to Patients With NSTEMI. Critical Pathways in Cardiology, 2020, 19, 166-172.	0.2	1
88	ED to catheterization laboratory: a roundtable integrating trials with practice. American Journal of Emergency Medicine, 2011, 29, 1203-1216.	0.7	0
89	Current and Future Options for Anticoagulant Therapy in the Acute Management of ACS. Current Treatment Options in Cardiovascular Medicine, 2013, 15, 21-32.	0.4	0
90	Cardiovascular Risk in Diabetes Mellitus: Cause and Effect. Current Emergency and Hospital Medicine Reports, 2014, 2, 16-25.	0.6	0

#	ARTICLE	IF	CITATIONS
91	The Impact of Risk Stratification of Venous Thromboembolism on Complexity and Site of Management. <i>Current Emergency and Hospital Medicine Reports</i> , 2015, 3, 100-108.	0.6	0
92	Letter to the Editor. <i>Journal of Intensive Care Medicine</i> , 2016, 31, 70-71.	1.3	0
93	Antidotes for Bleeding Caused by Novel Oral Anticoagulants. <i>Circulation</i> , 2016, 133, e18-9.	1.6	0
94	ISSUE INTRODUCTION: The Diminishing Role of Aspirin in Cardiovascular Medicine: A Special Supplement to <i>The American Journal of Cardiology</i> . <i>American Journal of Cardiology</i> , 2021, 144, S1.	0.7	0
95	Higher daily pain severity after emergency department visits is associated with lower return-to-work rates. <i>American Journal of Emergency Medicine</i> , 2021, 45, 48-53.	0.7	0
96	New Functional Imaging Technology to Differentiate between Chronic Obstructive Pulmonary Disease and Heart Failure. <i>Western Journal of Emergency Medicine</i> , 2011, 12, 17-8.	0.6	0